The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
Hong-Yuan Shen(Xijing Hospital), Xiequn Chen(Northwestern Polytechnical University)
Cited by 22
Related Papers
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
|Cell Death and Disease|2020|23